Commercialization Grant

Due: March 27, 2026

The Medical CBRN Defense Consortium (MCDC) was formed in response to the government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical, pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.

Through the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), the Medical Countermeasures Systems (MCS) Joint Project Management Office is always looking for innovative, safe and effective medical solutions to counter CBRN threats. The usage of an OTA allows government to partner with the MCDC to leverage cutting edge R&D and develop prototypes from commercial sources. This gives MCS an agile and flexible way to develop medical countermeasures using new and innovative technology.

Responding to this opportunity requires membership in the Medical CBRN Defense Consortium (MCDC). This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity. 

Complete the form below and a program representative will reach out to you shortly to support you through the process.

Contact MCDC: Commercialization Grant
First
Last